Rafferty Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Rafferty Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595K	Sell	44,714 -26,682	-37%	-$260K	﹤0.01%	866
2026 Q1	$665K	Sell	71,396 -12,017	-14%	-$105K	﹤0.01%	854
2025 Q4	$626K	Buy	+83,413	New	+$846K	﹤0.01%	878
2024 Q4	–	Sell	-90,348	Closed	-$977K	–	1154
2024 Q3	$977K	Sell	90,348 -5,217	-5%	-$86.6K	﹤0.01%	806
2024 Q2	$2.01M	Sell	95,565 -96,816	-50%	-$2.43M	0.01%	637
2024 Q1	$6.13M	Buy	192,381 +65,792	+52%	+$1.68M	0.02%	424
2023 Q4	$2.56M	Sell	126,589 -34,697	-22%	-$457K	0.01%	613
2023 Q3	$2.05M	Sell	161,286 -35,869	-18%	-$600K	0.01%	605
2023 Q2	$3.56M	Buy	197,155 +62,367	+46%	+$1.15M	0.02%	488
2023 Q1	$2.32M	Buy	134,788 +86,855	+181%	+$1.69M	0.02%	564
2022 Q4	$1.06M	Buy	+47,933	New	+$740K	0.01%	740
2022 Q2	–	Sell	-71,774	Closed	-$1.08M	–	1162
2022 Q1	$1.08M	Sell	71,774 -3,939	-5%	-$61.9K	0.01%	762
2021 Q4	$1.66M	Buy	+75,713	New	+$1.86M	0.01%	722

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Rafferty Asset Management's FDMT Position: Q2 2026 in Review

Rafferty Asset Management reduced its 4D Molecular Therapeutics (FDMT) stake by 37% in Q2 2026, selling an estimated $260K and leaving 44,714 shares worth $595K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Rafferty Asset Management first reported a position in FDMT in Q4 2021 and has held it in 13 quarters since. The position peaked at $6.13M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Rafferty Asset Management held 44,714 shares of 4D Molecular Therapeutics worth $595K as of Q2 2026.
Rafferty Asset Management sold 26,682 4D Molecular Therapeutics shares in Q2 2026, an estimated $260K.
4D Molecular Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #866 holding.
Rafferty Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 13 quarters since.
Rafferty Asset Management's 4D Molecular Therapeutics position peaked at $6.13M in Q1 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.